Stockscreener 앱 받기
1.14
8.06%
-0.10
시간 외 거래:
1.06
-0.08
-7.02%
전일 마감가:
$1.24
열려 있는:
$1.19
하루 거래량:
251.41K
Relative Volume:
0.21
시가총액:
$2.67M
수익:
-
순이익/손실:
$-98.30M
주가수익비율:
-0.1581
EPS:
-7.2097
순현금흐름:
$-8.72M
1주 성능:
+8.55%
1개월 성능:
-0.87%
6개월 성능:
-76.40%
1년 성능:
-85.71%
1일 변동 폭
$1.08
$1.3331
1주일 범위
$0.99
$1.42
52주 변동 폭
$0.9801
$25.00
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
명칭
Zyversa Therapeutics Inc
전화
908-370-5102
주소
217 W. MAIN STREET, SOMERVILLE
ZVSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
1.14 | 2.67M | 0 | -98.30M | -8.72M | -194.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zyversa Therapeutics Inc 주식(ZVSA)의 최신 뉴스
Analysts Provide An Important Insights On ZyVersa Therapeutics Inc (ZVSA) - Stocks Register
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco - The Manila Times
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco - GlobeNewswire
ZyVersa to Showcase Breakthrough Kidney Disease Drug at JPM Healthcare Conference 2025 - StockTitan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZVSA stock touches 52-week low at $1.03 amid sharp annual decline - Investing.com Canada
OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR - MSN
ZyVersa reports progress on stroke-related heart injury treatment By Investing.com - Investing.com Nigeria
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ZyVersa reports progress on stroke-related heart injury treatment - Investing.com
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial - GlobeNewswire
ZyVersa's IC 100 Shows Promise in Stroke Prevention, Phase 1 Trials Set for 2025 | ZVSA Stock News - StockTitan
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeu - GuruFocus.com
ZyVersa Therapeutics Reports Q3 Progress and Outlook - TipRanks
ZyVersa Therapeutics Inc (ZVSA) Quarterly 10-Q Report - Quartzy
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Plans Key Clinical Trials as Q3 Losses Narrow, Faces Cash Needs | ZVSA Stock News - StockTitan
ZVSA stock plunges to 52-week low, hitting $1.34 amid market challenges - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 3.56% - Investing.com India
ZyVersa Therapeutics, Inc. (ZVSA): A 38.8% Stock Surge Highlights Innovative Approach to Inflammatory Disease with IC 100 - BP Journal
Agrify Corporation (AGFY): Strategic Restructuring and New Leadership Boosts Stock by 33% as Green Thumb Invests $20 Million - BP Journal
Curis Inc. (CRIS) Stock Surges 5.08% Amid Strong Biotech Sector Performance - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge" - openPR
Wall Street-Heavily Traded - WDRB
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings - Benzinga
S&P 500 Gains 1%; Vimeo Shares Spike Higher - Benzinga
Bionomics Limited (BNOX): Stock Soars Over 162% Following Milestone Payment from Carina Biotech - BP Journal
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
ZyVersa (ZVSA) Stock Gains Momentum With Latest Research - Stocks Telegraph
U.S. Stock market: Zoomcar Holdings up 87.10%, Avalon GloboCare jumps 57.14%, Vimeo rises 44.07% among top gainers - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
ZyVersa reports progress on obesity inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa reports progress on obesity inflammation treatment - Investing.com India
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - The Manila Times
ZyVersa Therapeutics Highlights Published Data - GlobeNewswire
ZyVersa's Breakthrough: New Data Shows Promise for Type 2 Diabetes Prevention | ZVSA Stock | ZVSA Stock News - StockTitan
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - The Manila Times
ZyVersa Therapeutics Highlights Review Article Supporting - GlobeNewswire
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
ZyVersa reports obesity-linked brain inflammation study By Investing.com - Investing.com Canada
ZyVersa reports obesity-linked brain inflammation study - Investing.com
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewswire
ZVSA stock touches 52-week low at $2.07 amid sharp annual decline - Investing.com Canada
ZVSAZyVersa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
ZyVersa advances obesity drug with key milestones ahead - Investing.com India
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - The Manila Times
ZyVersa advances obesity drug with key milestones ahead By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter - GlobeNewswire
Zyversa Therapeutics Inc (ZVSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):